James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Hey Elon, Here’s the BEST Way to Silence a Critical Media

Tesla CEO Elon Musk is tired of being under fire, and who can blame him? But the bulk of the critiques are self-induced.

3 (More) Artificial Intelligence Stocks You Hadn’t Thought Of

Looking for artificial intelligence stocks? Think outside the box, beyond IBM and Microsoft. Off-the-radar players like NXP, Box and DXC Technology have earned a look as well.

Electronic Arts Inc. Is Melding Real Sports and eSports

It's not a reason to rush in and buy EA stock, but there's no doubt eSports could be huge for Electronic Arts.

Sony’s EMI Acquisition Could Shift the Music Industry’s Balance of Power

It's not a reason to buy or sell SNE stock yet, but the Sony purchase of EMI should give it a commanding control of a brutal business.

3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

Pfizer (PFE) has more going for it in the field of biosimilars than you might realize, but more than anything it's proven it can play in this arena.